Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  IQVIA Holdings Inc.    IQV

IQVIA HOLDINGS INC.

(IQV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
191.44(c) 189.42(c) 189.36(c) 188.11(c) 187.79(c) Last
617 112 607 700 529 238 568 215 977 338 Volume
+0.19% -1.06% -0.03% -0.66% -0.17% Change
More quotes
Financials (USD)
Sales 2020 11 202 M - -
Net income 2020 331 M - -
Net Debt 2020 10 423 M - -
P/E ratio 2020 110x
Yield 2020 -
Sales 2021 12 505 M - -
Net income 2021 694 M - -
Net Debt 2021 10 314 M - -
P/E ratio 2021 51,7x
Yield 2021 -
Capitalization 36 004 M 36 004 M -
EV / Sales 2020 4,14x
EV / Sales 2021 3,70x
Nbr of Employees 68 000
Free-Float 74,5%
More Financials
Company
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions,... 
More about the company
Notations Surperformance© of IQVIA Holdings Inc.
Trading Rating : Investor Rating :
More Ratings
All news about IQVIA HOLDINGS INC.
01/15SECTOR UPDATE : Health Care Stocks Rising to Conclude Volatile Week
MT
01/14TEVA PHARMACEUTICAL INDUSTRIES : Unveils Generic Version of Female Contraceptive..
MT
01/05IQVIA : to Help Improve Laboratoires Thea's Customer-Facing Business Functions
MT
01/05IQVIA : Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global ..
BU
01/03Factbox-How AstraZeneca-Oxford developed Britain's homegrown COVID-19 vaccine
RE
2020FACTBOX : How AstraZeneca-Oxford developed Britain's homegrown COVID-19 vaccine
RE
2020Lupin Gets US FDA Approval for Rufinamide Oral Suspension
MT
2020IQVIA-Quest Diagnostics Joint Venture Q2 Form Marketing Partnership With Adap..
MT
2020IQVIA : Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With A..
BU
2020Lupin Gets US FDA Approval for Colesevelam Hydrochloride Tablets
MT
2020IQVIA : Mizuho Securities Adjusts IQVIA Holdings PT to $200 From $190, Maintains..
MT
2020IQVIA : Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, ..
BU
2020IQVIA : Selected to Support Servier's Research, Development Transformation Initi..
MT
2020IQVIA : and Servier Collaborate to Reinvent Clinical Development
BU
2020Aurobindo Pharma Gets US FDA Nod for Sedative Jab
MT
More news
News in other languages on IQVIA HOLDINGS INC.
2020Corona-Krise wirbelt den Apothekenmarkt weiter durcheinander
2020ANALYSTEN :  Versandapotheken haben Marktanteil in der Krise gesteigert
2020IQVIA HOLDINGS INC. : publication des résultats trimestriels
2020IQVIA HOLDINGS INC. : Veröffentlichung des Quartalsergebnisses
2020AUSBLICK ALCON : Q2-Umsatz von 1,2 Milliarden US-Dollar erwartet
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | IQV | US46266C1053 | MarketScreener
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 198,21 $
Last Close Price 187,79 $
Spread / Highest target 20,9%
Spread / Average Target 5,55%
Spread / Lowest Target -16,4%
EPS Revisions
Managers and Directors
NameTitle
Ari Bousbib Chairman, President & Chief Executive Officer
James Grant Berkshire Senior Vice President-Business Operations
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
John M. Leonard Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IQVIA HOLDINGS INC.4.81%36 004
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
SEAGEN INC.6.06%33 601
HANGZHOU TIGERMED CONSULTING CO.,LTD0.37%21 655